Ensuring Access to Optimal Therapy in CF: The ENACT Study
Ensuring Access to Optimal Therapy in CF: The ENACT Study
Recruiting · NCT07148739 · Registry updated 2026-06-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ensuring Access to Optimal Therapy in CF: The ENACT Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Recruiting | Phase 4 | 2026-06-02 | NCT07148739 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Arkansas Children's Hospital Research Institute | 37 |
| National Heart, Lung, and Blood Institute (NHLBI) | 791 |
| National Institutes of Health (NIH) | 667 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Arkansas Children's Hospital | Little Rock | United States | 3 |
| The University of Alabama at Birmingham | Birmingham | United States | 17 |
| University of Washington | Seattle | United States | 172 |